CN105566215A - Preparation method of Stivarga - Google Patents
Preparation method of Stivarga Download PDFInfo
- Publication number
- CN105566215A CN105566215A CN201410555548.2A CN201410555548A CN105566215A CN 105566215 A CN105566215 A CN 105566215A CN 201410555548 A CN201410555548 A CN 201410555548A CN 105566215 A CN105566215 A CN 105566215A
- Authority
- CN
- China
- Prior art keywords
- picoline
- reaction
- methane amide
- chloro
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a preparation method of Stivarga. New compound 4-(3-fluorophenoxy)-N-methylpyridine-2-methanamide(5) and 4-(3-fluorine-4-aminophenoxy)-N-methylpyridine-2-methanamide(6) are introduced as intermediates. Through the introduction of the intermediates, the invention provides the preparation method of the Stivarga, which is mild in reaction condition, simple in after-treatment, high in reaction yield and purity, low in cost and more reasonable.
Description
Technical field
The invention belongs to medical art, provide the synthetic method of a kind of Mutiple Targets kinase inhibitor Rui Gefeini, more specifically to by introducing 4-(3-fluorophenoxy)-N-picoline-2-methane amide (5), 4-(the fluoro-4-nitrophenoxy of 3-)-N-picoline-2-methane amide (6) and 4-(the fluoro-4-amino-benzene oxygen of 3-)-N-picoline-2-methane amide (7) as the preparation method of the Rui Gefeini of intermediate.
Background technology
Rui Gefeini (regorafenib, 1) be researched and developed by Beyer Co., Ltd, first is proved the small molecules Mutiple Targets kinase inhibitor that can be used for treating the transitivity rectum cancer (mCRC), approval listing in September, 2012 U.S. food Drug Administration (FDA), commodity are called Stivarga.It effectively can block tumor cell proliferation, Tumor suppression vasculogenesis, modulate tumor microenvironment, has good anti-tumor activity.Medicines structure and Xarelto only have fine difference, but it is stronger to the restraining effect of VEGFR-2, PDGFR-β, FGFR-1 and c-Kit, can also suppress Tie-2, have blood vessel formation against function widely.Complete Rui Gefeini for metastatic colorectal carcinoma and large-scale random international, multi-center III clinical trial phase of gastrointestinal stromal tumors (GISTs) two at present, its single medicine or actively develop at present with the clinical study of other malignant tumours of standard chemotherapeutic agents combination therapy.Structural formula is:
At present, about the reference of Rui Gefeini preparation method comprises: patent WO2005009961, WO2008089388, WO2011130728, WO2012012404.The preparation method of the Rui Gefeini provided in these documents is with pyridine-2-formic acid for starting raw material, through chloro, ammonia solution, becomes ether and addition reaction to obtain Rui Gefeini.
In ammonolysis reaction, these documents prepare the hydrochloride of intermediate 4 by following steps: the brown oil of intermediate 4 is dissolved in organic solvent, rear by dripping concentrated hydrochloric acid salify.The method yield is low, and compound proterties is not good, and therefore, the salifying method of the present invention to intermediate 4 improves.
In this route becomes ether to react; according to the method that above-mentioned document is specifically reported; although reaction only has a step, reaction needed is carried out in nitrogen strict protection with make solvent with DMA under, and side reaction is a lot; very easily produce and the by product that amino docks and phenol is oxidized; aftertreatment is numerous and diverse, and product purification is more difficult, needs pillar layer separation to purify; yield is not high, is not suitable for suitability for industrialized production.Given this, the present invention devises new synthetic route.
Summary of the invention
The object of the invention is for above Problems existing with not enough, a kind of effective ways preparing Rui Gefeini are provided, by introducing new compound 5 and 6 as intermediate, provide that a kind of reaction conditions milder, aftertreatment are simpler, reaction yield and purity is higher, cost is lower and the preparation method of method more reasonably Rui Gefeini.
Because compound 4-(3-fluorophenoxy)-N-picoline-2-methane amide (5) and 4-(the fluoro-4-amino-benzene oxygen of 3-)-N-picoline-2-methane amide (6) synthesize and first for the preparation of Rui Gefeini, therefore, the present invention includes the synthesis of compound 5 and 6 and the application in preparation Rui Gefeini thereof.
Synthetic route of the present invention is:
Preparation method of the present invention, comprises the following steps:
1) chlorination: pyridine-2-formic acid (2) and NaBr are added in chlorobenzene, slowly thionyl chloride is dripped under stirring, be warming up to 85 ~ 130 DEG C of reactions, react complete, be chilled to room temperature, concentrating under reduced pressure, the yellow oil (3) of a small amount of solid must be contained, backward its adds toluene, is directly used in the next step.
2) ammonolysis reaction: aqueous methylamine solution is chilled to-10 ~ 0 DEG C, slowly adds the toluene solution of 3 under stirring, control temperature is not higher than 50 DEG C, finish, room temperature reaction, react complete, divide water-yielding stratum toluene to extract, concentrating under reduced pressure organic phase, adds the organic solvent solution of hydrogenchloride wherein, suction filtration, filter cake is water-soluble, adjust pH to neutral with buck, suction filtration, drying, obtains the chloro-N-picoline of 4--2-methane amide (4).
Wherein, described organic solvent is selected from one or more in methylene dichloride, ether, acetone, tetrahydrofuran (THF), dioxane, ethyl acetate, ethanol or methyl alcohol.
Preferred organic solvent is dioxane.
Wherein, in ammonolysis reaction, described buck is the aqueous solution or the ammoniacal liquor of sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, salt of wormwood, saleratus or sodium bicarbonate.
Preferred buck is aqueous sodium hydroxide solution.
3) ether reaction is become: add in organic solvent by 3-fluorophenol and alkali, stir 30min, after add the chloro-N-picoline of 4--2-methane amide (4), be warming up to 70 ~ 180 DEG C of reactions, obtained 4-(3-fluorophenoxy)-N-picoline-2-methane amide (5).
Wherein, described organic solvent is selected from one or more the mixed solvent in acetonitrile, DMF, DMA, DMSO, NMP, benzene, toluene and chlorobenzene.
Preferred organic solvent is DMF.
Wherein, described alkali is selected from the one in hydrogen sodium, potassium tert.-butoxide, sodium hydroxide, potassium hydroxide, lithium hydroxide, salt of wormwood, sodium carbonate, cesium carbonate, sodium methylate, potassium methylate or sodium ethylate.
Preferred alkali is potassium hydroxide.
4) nitration reaction: intermediate 5 is dissolved in the vitriol oil, slowly instill the nitration mixture of concentrated nitric acid-vitriol oil afterwards, control temperature is lower than 50 DEG C of reactions, react complete, be poured in water, organic solvent extraction, merge organic phase, successively with saturated common salt washing, drying, suction filtration, concentrating under reduced pressure, obtain yellow oil (6), be not purifiedly directly used in the next step.
Wherein, the volume ratio of described concentrated nitric acid-vitriol oil nitration mixture is 1:10 ~ 10:1, and preferred volume ratio is 1:3; Described temperature is lower than 50 DEG C, and preferable temperature is-10 ~ 0 DEG C.
Wherein, described organic solvent is selected from one or more the mixed solvent in methylene dichloride, ethyl acetate, benzene, toluene, chlorobenzene, ether, chloroform, tetracol phenixin and hexanaphthene.
Preferred solvent is one or more the mixed solvent in methylene dichloride, ethyl acetate, toluene, ether.
5) reduction reaction: iron powder, ammonium chloride, concentrated hydrochloric acid are added in the mixed solvent of organic solvent-water, reflux 30min, in rear instillation, step reaction oily matter, reacts complete, suction filtration while hot, concentrating under reduced pressure filtrate, adds organic solvent dissolution resistates, acid rinsing, water layer organic solvent extraction, merge organic phase, drying, suction filtration, evaporate to dryness, obtain 4-(the fluoro-4-amino-benzene oxygen of 3-)-N-picoline-2-methane amide (7).
Wherein, described mixed solvent system has alcohol-water, methanol-water, tetrahydrofuran (THF)-water, acetone-water, toluene-water, and described volume ratio is 1:5 ~ 5:1.
Preferred mixed solvent is alcohol-water, and preferred volume ratio is 4:3.
Wherein, described organic solvent is selected from one or more the mixed solvent in methylene dichloride, ethyl acetate, benzene, toluene, chlorobenzene, ether, chloroform, tetracol phenixin and hexanaphthene.
Preferred solvent is one or more the mixed solvent in methylene dichloride, ethyl acetate, toluene, ether.
Wherein, selected sour water is one or more the mixed solvent in hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, oxalic acid, acetic acid, ammonium sulfate or ammonium chloride; Sour water pH2 ~ 6.Preferred sour water is the hydrochloric acid of 10%.
6) carbonylation reaction: solid phosgene is dissolved in organic solvent, be chilled to-10 ~ 0 DEG C, add the chloro-3-5-trifluoromethylaniline (9) of 4-, back flow reaction 1h in batches, underpressure distillation, collects cut 4-chloro-3-trifluoromethyl phenylisocyanate (8) of 120 DEG C/0.1MPa.
7) addition reaction: intermediate 7 and 4-chloro-3-trifluoromethyl phenylisocyanate (8) are dissolved in organic solvent, room temperature reaction 30min, suction filtration, washing leaching cake, drying, obtains target compound 4-(4-(3-(the chloro-3-trifluoromethyl of 4-) urea groups)-3-fluorophenoxy)-N-picoline-2-methane amide (1);
The present invention prepares Rui Gefeini by introducing intermediate 5 and 6, significantly reduces side reaction, improves product purity and yield, and reach the object reducing production cost and shorten reaction time, in particular, simplify aftertreatment, this is very important in suitability for industrialized production.
On the basis of the above, according to ordinary technical knowledge and the customary means of this area, not departing under the present invention's above-mentioned basic fundamental thought prerequisite, the amendment of various ways, replacement or change can also be made.
Embodiment
By the description of following embodiment, foregoing of the present invention is described in further detail.For a person skilled in the art, this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following method and describes; All technology realized based on foregoing of the present invention all belong to scope of the present invention.
1, the synthesis of 4-Chloro-2-Pyridyle formyl chloride hydrochloride (3)
30.0g (244mmol) pyridine-2-formic acid (2) and 4.0g (39mmol) NaBr are added in 40mL chlorobenzene, stirs lower slowly dropping 70mL thionyl chloride, finish, be warming up to 85 DEG C, reaction 23h.Be chilled to room temperature, concentrating under reduced pressure, the yellow oil of a small amount of solid must be contained.Backward its adds 120mL toluene, is directly used in the next step.
2, the synthesis of the chloro-N-picoline of 4--2-methane amide (4)
97mL40% (826mmol) aqueous methylamine solution is added in 75mL water, be chilled to 0 DEG C, under stirring, slowly add the toluene solution of above-mentioned 3, control temperature of reaction lower than 50 DEG C, finish, room temperature reaction 7h, point water-yielding stratum toluene extracts, and merges organic phase, concentrating under reduced pressure, the dioxane solution of 150mL hydrogenchloride is added, stirring at room temperature 1h, suction filtration to resistates.Filter cake is dissolved in 150mL water, adjusts pH to neutral with the 20%NaOH aqueous solution, suction filtration, dry, obtain yellow powder (4).Two-step reaction total recovery 88.3%, purity 99.5% (literature value: two-step reaction total recovery 67%, purity about 96%).MSm/z:171.1,172.1,173.1[M+H]
+,193.1[M+Na]
+.
1HNMR(400MHz,DMSO-d
6)δ:8.87(s,1H),8.63(d,J＝5.3Hz,1H),8.03(d,J＝2.1Hz,1H),7.77(dd,J＝2.1,5.3Hz,1H),2.84(d,J＝4.8Hz,3H).
3, the synthesis of 4-(3-fluorophenoxy)-N-picoline-2-methane amide (5)
8.5g (76mmol) 3-fluorophenol and 7.8g (141mmol) potassium hydroxide are added in 100mLDMF, stirring at room temperature 30min, after add 10.0g (59mmol) intermediate 4, be warming up to 100 DEG C of reactions.React complete, be cooled to room temperature, by its impouring 800mL water, stirring and crystallizing, suction filtration, dry, obtain off-white color crystal (5).Yield 81.3%, purity 99.2%, mp197 ~ 198 DEG C.MSm/z:247.2[M+H]
+,269.0[M+Na]
+,285.0[M+K]
+.
1HNMR(600MHz,DMSO)δ:8.79(d,J＝4.4Hz,1H),8.55(d,J＝5.6Hz,1H),7.56(dd,J＝15.1,8.1Hz,1H),7.45(d,J＝2.5Hz,1H),7.28–7.11(m,3H),7.10(dd,J＝8.1,1.7Hz,1H),2.80(d,J＝4.9Hz,3H).
4, the synthesis of 4-(the fluoro-4-nitrophenoxy of 3-)-N-picoline-2-methane amide (6)
6.0g (25mmol) intermediate 5 is dissolved in the 30mL vitriol oil, the rear nitration mixture being slowly added dropwise to 2.5mL concentrated nitric acid-vitriol oil (volume ratio 1:3), control temperature-10 ~ 0 DEG C reaction 1.5h.Be poured in 700mL water, extraction into ethyl acetate, merge organic phase, saturated common salt water washing, dry, suction filtration, evaporate to dryness, obtains yellow oil (6), is not purifiedly directly used in the next step.MSm/z:292.0[M+H]
+,314.0[M+Na]
+,330.0[M+K]
+,605.0[2M+Na]
+.
5, the synthesis of 4-(the fluoro-4-amino-benzene oxygen of 3-)-N-picoline-2-methane amide (7)
6.3g (113mmol) iron powder, 0.75g (14mmol) ammonium chloride and 1.7mL (42mmol) concentrated hydrochloric acid are added in 40mL alcohol-water (volume ratio 4:3) mixed solvent, temperature rising reflux 30min.Add the oily matter of intermediate 6, back flow reaction 1h.Suction filtration while hot, evaporate to dryness filtrate, adds acetic acid ethyl dissolution resistates, 10% salt acid elution, and aqueous layer with ethyl acetate extracts, and merges organic phase, and saturated common salt is washed, and anhydrous magnesium sulfate drying, suction filtration, evaporate to dryness filtrate, obtains brick-red solid (7).Two-step reaction total recovery 76.6%, purity 99.8% (literature value: yield 47%).MSm/z:261.9[M+H]
+,283.9[M+Na]
+.
1HNMR(400MHz,DMSO-d
6)δ:8.80(q,J＝4.7Hz,1H),8.50(d,J＝5.6Hz,1H),7.40(d，J＝2.4Hz，1H),7.13(dd，J＝2.8,5.6Hz,1H),7.08(dd,J＝2.4,12Hz,1H),6.98(t,J＝8.8Hz,1H),6.85(dd,J＝2.8,8.4Hz,1H),5.50(brs,2H),2.80(d,J＝4.8Hz,3H).
6, the synthesis of 4-chloro-3-trifluoromethyl phenylisocyanate (8)
Under stirring at room temperature, by 12.0g (40mmol)) solid phosgene (BTC) is dissolved in 120mL ethyl acetate, be chilled to 0 DEG C, add the chloro-3-5-trifluoromethylaniline (9) of 20.0g4-in batches, be warming up to 80 DEG C, back flow reaction 1h, underpressure distillation, collect 120 DEG C/0.1MPa cut, after solidification, obtain white crystal.Yield 94.3%, purity 98.9%.
1HNMR(400MHz,CDCl
3)δ:7.48(d,J＝8.5Hz,1H),7.44(d,J＝2.4Hz,1H),7.22(dd,J＝2.3,8.5Hz,1H).
7, the synthesis of 4-(4-(3-(the chloro-3-trifluoromethyl of 4-) urea groups)-3-fluorophenoxy)-N-picoline-2-methane amide (1)
3.0g (11mmol) intermediate 7 is dissolved in 20mL ethyl acetate, add 3.5g (16mmol)) 4-chloro-3-trifluoromethyl phenylisocyanate (8), room temperature reaction 30min, suction filtration, with 50mL washed with diethylether filter cake, suction filtration, dry, obtain lightpink powder (1).Yield 94.5%, purity 99.8%.MSm/z:480.9,481.7,482.9[M-H]
-,504.9,505.8,506.9[M+Na]
+.
1HNMR(400MHz,DMSO-d
6)δ:9.55(s,1H),8.79(q,J＝4.8Hz,1H),8.75(d,J＝2.3Hz,1H),8.53(d,J＝5.6Hz,1H),8.16(t,J＝9.0Hz,1H),8.13(t,J＝1.5Hz,1H),7.63(d,J＝1.5Hz,2H),7.43(d,J＝2.6Hz,1H),7.34(dd,J＝11.6,2.7Hz,1H),7.21–7.17(m,1H),7.08(ddd,J＝8.9,2.8,1.3Hz,1H),2.80(d,J＝4.8Hz,3H)。
Claims (11)
1. Yi Zhong Rui Gefeini (
1) preparation method, comprise chloro, ammonia solution, become ether, nitrated, reduction, addition reaction, it is characterized in that, through following steps:
1) chlorination: pyridine-2-formic acid (
2) with thionyl chloride under the katalysis of NaBr, the hydrochloride of obtained compound 4-chloro-2-pyridinecarboxylic chloride (
3);
2) ammonolysis reaction: the hydrochloride of 4-Chloro-2-Pyridyle formyl chloride (
3) react with aqueous methylamine solution, obtain 4-chloro-
n-picoline-2-methane amide (
4);
3) ether reaction is become: 4-is chloro-
n-picoline-2-methane amide (
4) with 3-fluorophenol under the effect of alkali, obtained 4-(3-fluorophenoxy)-
n-picoline-2-methane amide (
5);
4) nitration reaction: 4-(3-fluorophenoxy)-
n-picoline-2-methane amide (
5) react with concentrated nitric acid-vitriol oil nitration mixture, obtain 4-(the fluoro-4-nitrophenoxy of 3-)-
n-picoline-2-methane amide (
6);
5) reduction reaction: 4-(the fluoro-4-nitrophenoxy of 3-)-
n-picoline-2-methane amide (
6) through ferrous acid reduction, obtained 4-(the fluoro-4-amino-benzene oxygen of 3-)-
n-picoline-2-methane amide (
7);
6) addition reaction: 4-(the fluoro-4-amino-benzene oxygen of 3-)-
n-picoline-2-methane amide (
7) and 4-chloro-3-trifluoromethyl phenylisocyanate (
8) reaction, obtain target compound 4-(4-(3-(the chloro-3-trifluoromethyl of 4-) urea groups)-3-fluorophenoxy)-
n-picoline-2-methane amide (
1).
2. preparation method according to claim 1, is characterized in that,
4-described in step 6) chloro-3-trifluoromethyl phenylisocyanate (
8) by the chloro-3-5-trifluoromethylaniline of 4-(
9) react obtain with solid phosgene.
3. preparation method according to claim 1 and 2, is characterized in that,
The one-tenth ether reaction of step 3) is as follows: add in organic solvent by 3-fluorophenol and alkali, stirring 30min, after to add 4-chloro-
n-picoline-2-methane amide (
4), be warming up to 70 ~ 180
oc reacts, obtained 4-(3-fluorophenoxy)-
n-picoline-2-methane amide (
5).
4., according to the preparation method of claim 1-3 described in any one, it is characterized in that,
Step 4) nitration reaction is as follows: by 4-(3-fluorophenoxy)-
n-picoline-2-methane amide (
5) be dissolved in the vitriol oil, the nitration mixture of rear slow instillation concentrated nitric acid-vitriol oil, control temperature is lower than 50
oc reacts, and reacts complete, is poured in water, organic solvent extraction, merges organic phase, and saturated sodium-chloride water solution washs, dry, suction filtration, filtrate evaporate to dryness obtain yellow oil 4-(the fluoro-4-nitrophenoxy of 3-)-
n-picoline-2-methane amide (
6), be not purifiedly directly used in the next step.
5., according to the preparation method of claim 1-4 described in any one, it is characterized in that,
Step 5) reduction reaction is as follows: add in the mixed solvent of organic solvent-water by iron powder, ammonium chloride, concentrated hydrochloric acid, reflux 30min, rear instillation oily matter 4-(the fluoro-4-nitrophenoxy of 3-)-
n-picoline-2-methane amide (
6), react complete, while hot suction filtration, concentrating under reduced pressure filtrate, add organic solvent dissolution resistates, with acid rinsing, water layer organic solvent extraction, merges organic phase, dry, suction filtration, filtrate evaporate to dryness, obtain 4-(the fluoro-4-amino-benzene oxygen of 3-)-
n-picoline-2-methane amide (
7).
6., according to the preparation method of claim 1-5 described in any one, it is characterized in that,
Described ammonolysis reaction is as follows: aqueous methylamine solution is chilled to-10 ~ 0
oc, slowly add under stirring 4-Chloro-2-Pyridyle formyl chloride hydrochloride (
3) toluene solution, control temperature is not higher than 50
oc, finishes, room temperature reaction, reacts complete, and point water-yielding stratum toluene extracts, and concentrating under reduced pressure organic phase, adds the organic solvent solution of hydrogenchloride, suction filtration wherein, and filter cake is water-soluble, adjusts pH to neutral, suction filtration with buck, dry, obtains 4-chloro-
n-picoline-2-methane amide (
4); Wherein, described organic solvent is selected from methylene dichloride, ether, acetone, tetrahydrofuran (THF), dioxane, ethyl acetate, ethanol and methyl alcohol, and the organic solvent solution of described hydrogenchloride is the corresponding hydrogen chloride solution of above-mentioned organic solvent; Described buck is the aqueous solution or the ammoniacal liquor of sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, salt of wormwood, saleratus or sodium bicarbonate.
7. according to the preparation method of claim 1-6 described in any one, it is characterized in that: become in ether reaction, described organic solvent be selected from acetonitrile,
n,N-dimethyl formamide,
n,N-N,N-DIMETHYLACETAMIDE, dimethyl sulfoxide (DMSO),
none or more mixed solvent in-methyl-2-pyrrolidone, benzene, toluene and chlorobenzene; Described alkali is selected from hydrogen sodium, potassium tert.-butoxide, sodium hydroxide, potassium hydroxide, lithium hydroxide, salt of wormwood, sodium carbonate, cesium carbonate, sodium methylate, potassium methylate and sodium ethylate.
8., according to the preparation method of claim 1-7 described in any one, it is characterized in that: in nitration reaction, temperature of reaction is lower than 50
oc; The volume ratio of described concentrated nitric acid-vitriol oil nitration mixture is 1:10 ~ 10:1; Described organic solvent is selected from one or more the mixed solvent in methylene dichloride, ethyl acetate, benzene, toluene, chlorobenzene, ether, chloroform, tetracol phenixin and hexanaphthene.
9., according to the preparation method of claim 1-8 described in any one, it is characterized in that: in reduction reaction, described mixed solvent system has: alcohol-water, methanol-water, tetrahydrofuran (THF)-water, acetone-water and toluene-water, and described volume ratio is 1:5 ~ 5:1; Described organic solvent is selected from one or more the mixed solvent in methylene dichloride, ethyl acetate, benzene, toluene, chlorobenzene, ether, chloroform, tetracol phenixin and hexanaphthene; Selected sour water is one or more the aqueous solution in hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, oxalic acid, acetic acid, ammonium sulfate or ammonium chloride; Sour water pH2 ~ 6.
10. the compound of following structure:
。
The application of 11. compounds according to claim 10 in preparation Rui Gefeini.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410555548.2A CN105566215B (en) | 2014-10-17 | 2014-10-17 | A kind of Rui Gefeini preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410555548.2A CN105566215B (en) | 2014-10-17 | 2014-10-17 | A kind of Rui Gefeini preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105566215A true CN105566215A (en) | 2016-05-11 |
| CN105566215B CN105566215B (en) | 2018-02-16 |
Family
ID=55876916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410555548.2A Active CN105566215B (en) | 2014-10-17 | 2014-10-17 | A kind of Rui Gefeini preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105566215B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106588760A (en) * | 2016-12-20 | 2017-04-26 | 青岛辰达生物科技有限公司 | Greg Phineas intermediate preparation process |
| CN108610284A (en) * | 2018-04-08 | 2018-10-02 | 梯尔希（南京）药物研发有限公司 | A kind of preparation method of Rui Gefeini derivatives |
| CN110183377A (en) * | 2019-07-16 | 2019-08-30 | 浙江工业大学上虞研究院有限公司 | A kind of synthetic method of anticancer drug Rui Gefeini |
| CN110229099A (en) * | 2018-03-05 | 2019-09-13 | 连云港恒运药业有限公司 | A method of preparing Sorafenib key intermediate |
| CN112851577A (en) * | 2019-11-26 | 2021-05-28 | 齐鲁制药有限公司 | Preparation method of regorafenib |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1856469A (en) * | 2003-07-23 | 2006-11-01 | 拜尔医药品股份有限公司 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| WO2008089388A2 (en) * | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
| CN102459180A (en) * | 2009-06-09 | 2012-05-16 | 江苏迈度药物研发有限公司 | Urea derivatives as kinase inhibitors |
| CN103079567A (en) * | 2010-04-17 | 2013-05-01 | 拜尔健康护理有限责任公司 | Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions |
-
2014
- 2014-10-17 CN CN201410555548.2A patent/CN105566215B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1856469A (en) * | 2003-07-23 | 2006-11-01 | 拜尔医药品股份有限公司 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| WO2008089388A2 (en) * | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
| CN102459180A (en) * | 2009-06-09 | 2012-05-16 | 江苏迈度药物研发有限公司 | Urea derivatives as kinase inhibitors |
| CN103079567A (en) * | 2010-04-17 | 2013-05-01 | 拜尔健康护理有限责任公司 | Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions |
Non-Patent Citations (1)
| Title |
|---|
| 刘亚方等: "瑞格拉非尼（Regorafenib）的合成", 《精细化工中间体》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106588760A (en) * | 2016-12-20 | 2017-04-26 | 青岛辰达生物科技有限公司 | Greg Phineas intermediate preparation process |
| CN110229099A (en) * | 2018-03-05 | 2019-09-13 | 连云港恒运药业有限公司 | A method of preparing Sorafenib key intermediate |
| CN110229099B (en) * | 2018-03-05 | 2023-02-21 | 连云港恒运药业有限公司 | Method for preparing sorafenib key intermediate |
| CN108610284A (en) * | 2018-04-08 | 2018-10-02 | 梯尔希（南京）药物研发有限公司 | A kind of preparation method of Rui Gefeini derivatives |
| CN110183377A (en) * | 2019-07-16 | 2019-08-30 | 浙江工业大学上虞研究院有限公司 | A kind of synthetic method of anticancer drug Rui Gefeini |
| CN112851577A (en) * | 2019-11-26 | 2021-05-28 | 齐鲁制药有限公司 | Preparation method of regorafenib |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105566215B (en) | 2018-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105566215A (en) | Preparation method of Stivarga | |
| CN104945299B (en) | A kind of high-efficiency synthesis method of vildagliptin | |
| CN106349245A (en) | Sitagliptin phosphate impurities, method for preparing same and application of sitagliptin phosphate impurities | |
| CN106928236A (en) | A kind of synthesis technique of Rui Boxini | |
| CN103570633B (en) | The preparation method of Gefitinib | |
| CN107216313A (en) | A kind of antineoplastic AZD9291 preparation method | |
| CN106366022A (en) | Intermediate used for AZD9291 preparation, and preparation method and application thereof | |
| CN103483324B (en) | The new preparation process of lapatinibditosylate | |
| CN104529895B (en) | Synthetic method of replacing nitrogen-containing heterocyclic compound | |
| CN103755628B (en) | The synthetic method of the iodo-5-bromopyridine of 2-amino-3- | |
| CN104311485B (en) | A kind of preparation method treating leukemic medicine bosutinib | |
| CN105949118A (en) | Preparation method of 2-aryl quinoline derivatives | |
| CN106883175A (en) | A kind of preparation method of tolvaptan | |
| CN104844590B (en) | A kind of N methyl Ciprofloxacin (rhodanine beta-unsaturated ketone) amide derivatives and its preparation method and application | |
| CN102558042B (en) | 4-bromine-6-methylnicotinicacid and preparation method thereof | |
| CN107118215A (en) | A kind of preparation method for treating breast cancer medicines Rui Boxini intermediates | |
| CN103896858B (en) | The preparation technology of cytosine | |
| CN106008392B (en) | A kind of preparation method of the intermediate of cancer therapy drug Dasatinib | |
| CN104136422B (en) | The process for purification of compound, the manufacture method of compound and compound | |
| CN104402813B (en) | Novel method for synthesizing sorafenib | |
| CN109369772B (en) | Synthetic method and anti-tumor application of phenanthridine nitidine derivatives | |
| CN103896889B (en) | Lapatinib intermediate and its preparation method and application | |
| CN105130973A (en) | 5-Pyridyl-2-amino-benzo[d]oxazole derivatives, and preparation method and use thereof | |
| CN103145768A (en) | Method for preparing ferrocenecarboxaldehyde | |
| CN103772282B (en) | A kind of preparation method of the 3-tertiary butyl-1H-pyrazoles-4-formaldehyde |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |